MDMA and citalopram

PreclinicalSmall molecule

CCalifornia Pacific Medical Center Research Institute

MDMA and citalopram is one of 11 small molecule programs targeting Acute. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcuteCompleted

AcutePreclinical

Completed

Competition

Competitive Landscape

11 competitors in Acute

#DrugCompanyPhaseTrials

Fetroja

Shionogi

Approved

1 2

Orencia

Bristol-Myers Squibb

Phase 2

1 3

Vyvgart

Argenx

Phase 2

1 4

Dapansutrile

OOlatec Therapeutics LLC

Phase 3

1 5

Clemastine Fumarate

Novartis

Phase 2

1 6

Resotran

Takeda

Preclinical

1 7

Gen-1124

GGEn1E Lifesciences

Phase 2

1 8

Nicotine Pouches

JJohns Hopkins University

Phase 1

1 9

S-3,4-Methylenedioxymethamphetamine

UUniversity Hospital, Basel, Switzerland

Phase 1

2 10

R-3,4-Methylenedioxymethamphetamine

UUniversity Hospital, Basel, Switzerland

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute1 trial

Role of Serotonin in Acute and Subacute MDMA Effects

Completed·—·N/A·NCT00838305·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MDMA and citalopram. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MDMA and citalopram compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MDMA and citalopram. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — California Pacific Medical Center Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCalifornia Pacific Medical Center Research Institute

MDMA and citalopram

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute1 trial

References

Drug Info

Quick Facts

Related News